Three days
after pBDL surgery, the serum liver alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and ۷-glutamyl transferase (GGT) increased from baseline by 5. 3, 5. 7, 5. 3 and CP-673451 nmr 12. 1-fold respectively. Serum total bilirubin (TBil) levels increased by ≥100-fold. Seven days after surgery, AST and ALT levels had begun to normalize (3. 0 and 1. 7-fold) while ALP, GGT and total bilirubin values remained high at 4. 9, 22 and 103-fold compared to sham controls. This profile was sustained at 14 days post-surgery with elevations of 6. 8-fold for ALP, 15. 5-fold for GGT and 128-fold for TBil. SBA were also dramatically increased by 28.9-fold (30 uM to 873 uM) 7 days after surgery. SC-435 was administered to the test group
by once daily oral gavage at 10 mg/kg starting one day prior to pBDL surgery. Seven days after surgery ASBTi treatment had significantly reduced ALP by 58%, GGT by 48%, TBil by 49% and SBA by 52% compared to the untreated control group (p < 0.03 for all parameters). By 14 days post-surgery, ALP was reduced 75%, GGT by 65% and TBil by 67% compared to the untreated control group (p < 0.05 for all parameters). CONCLUSIONS: The pBDL model in HSD rats results in significant increases in SBA and serum liver enzymes from 3 to 14 days TGF-beta inhibitor after surgery that are characteristic of cholestasis and liver injury. Blocking bile acid recycling with SC-435 prevents dramatic increases in total SBA and liver biomarkers Thiamine-diphosphate kinase suggesting that an ASBTi may provide a new therapeutic option for the treatment of cholestatic liver disease by decreasing the accumulation of toxic bile acids and reducing the severity of cholestatic liver injury. Disclosures: Bradley T. Keller – Employment: Lumena Pharmaceuticals, Rivervest Venture Partners Bronislava
Gedulin – Employment: Lumena Pharmaceuticals The following people have nothing to disclose: Svetlana Nikoulina, Nicolaus Nazarenkov Background: Nucleotide oligomerization domain 2 (Nod2), a member of the Nod-like receptor (NLR) family of intracellular immune receptors, plays an important role in the defense against bacterial infection through binding to its ligand muramyl dipeptide (MDP). The aim of our study was to test whether Nod2 plays a role in experimental liver fibrosis. Methods and Results: In wild type and Nod2 mice cholestatic liver disease was induced by bile duct ligation for 3 weeks, and toxic liver disease was induced by 12 intraperitoneal injections of carbon tetrachloride. Nod2 deficiency protected mice from cholestatic but not toxin-induced liver injury and fibrosis. Bile duct ligated Nod2-/- showed significantly less liver injury (plasma ALT levels), and less fibrosis (Sirius red staining and collagen α1(I) QPCR); liver inflammation was not changed.